Back to Screener

Healthcare

Pliant Therapeutics, Inc.(PLRX)

Live Price

Offline

$1.16

-1.69% today

1Y Change

-7.20%

Window

Jun 23, 2025 โ†’ Jun 18, 2026

Market Cap
$70.00M
Revenue Growth
0.0%
EPS Growth
+30.0%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 23, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Pliant Therapeutics, Inc. (PLRX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.16 and down 7.2% across the available one-year price window (Jun 23, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +30.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +30.0%, free cash flow +19.2% with operating margin 0.0% and ROIC -73.2%. Stock Foundry combines PLRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PLRX

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PLRX Max Drawdown

-41.71%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PLRX and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

-0.46

Range -0.46 โ†’ -0.46

No analyst count

vs prior: -1.1%

Revenue Outlook

$0.0B

Range $0.0B โ†’ $0.0B

No analyst count

Consensus Spread

EPS spread0.0%
Revenue spreadโ€”

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

-0.46
Latest visible period
Q3 2026Q4 2027
6 visible pointstrend: -1.1%

Trend

Revenue trend

Average analyst revenue estimate

$0.0B
Latest visible period
Q3 2026Q4 2027
6 visible points

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q4 2027
Ends Dec 31, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.46
-0.46 to -0.46
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates
Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.45
-0.45 to -0.45
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates
Q2 2027
Ends Jun 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.45
-0.45 to -0.45
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates
Q1 2027
Ends Mar 31, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.44
-0.44 to -0.44
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates
Q4 2026
Ends Dec 31, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.40
-0.40 to -0.40
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates
Q3 2026
Ends Sep 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.38
-0.38 to -0.38
No analyst count
EPS: No analyst count
Apr 30, 05:03 AM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.